Literature DB >> 10505103

Myoblast transplantations lead to the expression of the laminin alpha 2 chain in normal and dystrophic (dy/dy) mouse muscles.

J T Vilquin1, B Guérette, J Puymirat, D Yaffe, F M Tomé, M Fardeau, M Fiszman, K Schwartz, J P Tremblay.   

Abstract

Laminin-2 is part of the basement membrane of the skeletal muscle fibers. The laminin alpha 2 chain is absent or drastically reduced in a subgroup of congenital muscular dystrophy patients, and in the severely affected dystrophic dy/dy mouse. We previously reported that heterogeneous primary mouse muscle cell cultures conferred laminin alpha 2 chain expression in dy/dy mice muscles upon cell transplantation. In the present study we investigated whether pure myoblast cell lines were able to confer laminin alpha 2 chain expression in vivo. We observed that: (1) xeno-transplantation of non-immortalized human myoblast in SCID mouse muscles allows human laminin alpha 2 chain expression; (2) allotransplantation of the permanent G8 mouse myoblast cell line in dy/dy muscles allows the expression of the murine laminin alpha 2 chain; and (3) allo-transplantation of the D7 dystrophic dy/dy cell line allows the formation of new and hybrid muscle fibers in dy/dy muscle in the absence of laminin alpha 2 chain expression. We conclude that normal myoblasts are able to restore the expression of an extracellular skeletal muscle protein and that the absence of laminin-2 does not prevent transplanted muscle cells from participating in the formation of myofibers. Myoblasts are, therefore, attractive tools for further exploration of gene complementation strategies in the animal models of congenital muscular dystrophy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10505103     DOI: 10.1038/sj.gt.3300889

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  8 in total

1.  Myoblasts and embryonic stem cells differentially engraft in a mouse model of genetic dilated cardiomyopathy.

Authors:  Cyril Catelain; Stéphanie Riveron; Aurélie Papadopoulos; Nathalie Mougenot; Adeline Jacquet; Karine Vauchez; Erica Yada; Michel Pucéat; Marc Fiszman; Gillian Butler-Browne; Gisèle Bonne; Jean-Thomas Vilquin
Journal:  Mol Ther       Date:  2013-02-26       Impact factor: 11.454

Review 2.  Influence of exercise and aging on extracellular matrix composition in the skeletal muscle stem cell niche.

Authors:  Koyal Garg; Marni D Boppart
Journal:  J Appl Physiol (1985)       Date:  2016-08-18

Review 3.  Myogenic Cell Transplantation in Genetic and Acquired Diseases of Skeletal Muscle.

Authors:  Olivier Boyer; Gillian Butler-Browne; Hector Chinoy; Giulio Cossu; Francesco Galli; James B Lilleker; Alessandro Magli; Vincent Mouly; Rita C R Perlingeiro; Stefano C Previtali; Maurilio Sampaolesi; Hubert Smeets; Verena Schoewel-Wolf; Simone Spuler; Yvan Torrente; Florence Van Tienen
Journal:  Front Genet       Date:  2021-08-02       Impact factor: 4.599

Review 4.  Enter the matrix: shape, signal and superhighway.

Authors:  Dane K Lund; D D W Cornelison
Journal:  FEBS J       Date:  2013-03-01       Impact factor: 5.542

5.  Skeletal muscle laminin and MDC1A: pathogenesis and treatment strategies.

Authors:  Kinga I Gawlik; Madeleine Durbeej
Journal:  Skelet Muscle       Date:  2011-03-01       Impact factor: 4.912

Review 6.  Advances in genetic hearing loss: CIB2 gene.

Authors:  Agnieszka Jacoszek; Agnieszka Pollak; Rafał Płoski; Monika Ołdak
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-10-22       Impact factor: 2.503

Review 7.  A Family of Laminin α2 Chain-Deficient Mouse Mutants: Advancing the Research on LAMA2-CMD.

Authors:  Kinga I Gawlik; Madeleine Durbeej
Journal:  Front Mol Neurosci       Date:  2020-04-21       Impact factor: 5.639

8.  Congenital muscular dystrophy-associated inflammatory chemokines provide axes for effective recruitment of therapeutic adult stem cell into muscles.

Authors:  Vitali Alexeev; Jacquelyn Olavarria; Paolo Bonaldo; Luciano Merlini; Olga Igoucheva
Journal:  Stem Cell Res Ther       Date:  2020-11-02       Impact factor: 6.832

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.